Is Protagonist Therapeutics, Inc (PTGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 9.7% / 30% | 0.1% / 30% | 62.56% / 5% | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 9.7% / 33% | 0.1% / 33% | 62.56% / 5% | ✗ NOT HALAL |
| MSCI | 1.5% / 33% | 84.9% / 33% | 0.7% / 33% | 62.56% / 5% | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 9.7% / 33% | 0.1% / 33% | 62.56% / 5% | ✗ NOT HALAL |
| FTSE | 1.5% / 33% | 84.9% / 33% | 0.7% / 50% | 62.56% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -677.1% | |
| Net Margin | -282.8% | |
| Return on Equity (ROE) | -20.2% | |
| Return on Assets (ROA) | -14.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $58M |
| Free Cash Flow | $56M |
| Total Debt | $10M |
| Debt-to-Equity | 1.7 |
| Current Ratio | 12.7 |
| Total Assets | $668M |
Price & Trading
| Last Close | $102.17 |
| 50-Day MA | $89.05 |
| 200-Day MA | $73.92 |
| Avg Volume | 775K |
| Beta | 2.2 |
|
52-Week Range
$39.60
| |
About Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Protagonist Therapeutics, Inc (PTGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Protagonist Therapeutics, Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Protagonist Therapeutics, Inc's debt ratio?
Protagonist Therapeutics, Inc's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.5%.
What are Protagonist Therapeutics, Inc's key financial metrics?
Protagonist Therapeutics, Inc has a market capitalization of $6.3B, and revenue of $46M. The company maintains a gross margin of 100.0% and a net margin of -282.8%. Return on equity stands at -20.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.